Ultragenyx sells a rare pediatric disease priority review voucher for $210 million, Viatris acquires Pacira BioSciences for $1.65 billion, and Peter Young surveys a steadying biopharma outlook.
News|Podcasts|March 12, 2026
Moving CAR-T Beyond Oncology
Author(s)Mike Hollan, Vincent Hennemand
Vincent Hennemand discusses using these types of therapies to develop treatments for autoimmune conditions.
Advertisement
Sail Biomedicine’s chief products and operations officer joined the Pharmaceutical Executive Podcast to discuss how researchers are developing CAR-T therapies that go beyond oncology. According to him, recent advancements have provided researchers with significant results using CAR-T to treat autoimmune conditions, such as lupus or rheumatoid arthritis.
- Hennemand explains the historical context of cell-based therapies in oncology, noting their success but limitations due to high costs and logistical challenges.
- Hennemand explains that Sail started in oncology but quickly pivoted to autoimmune disorders due to the suitability of RNA-based CAR T therapies.
- Hennemand highlights the advantages of RNA technology, such as quick expression and fast repopulation, which make it ideal for autoimmune disorders.
- Hennemand mentions that Sail’s closest competitors also started in oncology but have since shifted their focus to autoimmune disorders.
Advertisement
Related to this article
Caribou Biosciences discontinues its two allogeneic CAR-T programs, Kamal Biswas makes the case for continuous quality management maturity, and FDA approves Pfizer’s Tukysa as a first-line maintenance therapy in HER2-positive breast cancer.
Shionogi, Gate Bioscience, and Alector post a trio of new deals, Rajul Jain makes the case for social listening as a medical affairs strategic tool, and Doceree's Vijay Adapala argues that HCP engagement is a systems-design problem, not a communications one.
Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
Jewel Jones warns that pharma catches patient disengagement too late, CSL and Alentis Therapeutics join Jiangsu Nhwa and Somnivera in a day of new licensing deals, and Corxel's Bo Liang calls GLP-1's leap to bariatric-surgery-level efficacy the biggest surprise in obesity medicine.
Foghorn Therapeutics and Eli Lilly discontinue their SMARCA2 degrader program, Novartis licenses Abogen's autoimmune mRNA therapy while AstraZeneca, Daiichi Sankyo, and Summit Therapeutics team up on a breast cancer combination trial, and Corxel's Bo Liang makes the case for oral GLP-1 therapies.
Regeneron and Sanofi expand their antibody alliance with four new drug candidates, FDA approves Camzyos for adolescents with obstructive hypertrophic cardiomyopathy, and Michael Abrams questions digital health's savings claims to employers.
Improved financing conditions and accelerating M&A are creating new opportunities, but policy uncertainty, patent expirations and persistent funding pressures continue to shape the outlook for pharma and biotech.
Advertisement
Advertisement
Trending on PharmExec
1
Viatris Acquires Pacira BioSciences for $1.65 Billion
2
Ultragenyx to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
3
FDA Approves Tukysa Plus Trastuzumab and Pertuzumab as First-Line Maintenance Treatment for HER2-Positive Metastatic Breast Cancer
4
ESC 2026: GLP-1–Based Therapies Move Further into Mainstream Cardiovascular Care
5